Search

everythinglearnresearchcommunity

for

Search:↓

The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Effective symptom management in IBD improves quality of life and prevents complications.

Hair loss is common in IBD patients, and some medications may lower the risk.

Some drugs can cause skin reactions, which may improve when the drug is stopped, and rapid diagnosis and stopping the drug is crucial.

Thermography matched the patient's pain levels in a shingles case and might help diagnose shingles without a rash.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

TNF-alpha inhibitors can cause various immune-related skin issues.

Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.

Smart microneedles using advanced tech could improve psoriasis treatment.

Psoriasis worsens in winter in India due to less sunlight and dry skin, needing personalized treatment.

Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.

In Denmark from 1995 to 2016, hospital-treated alopecia areata cases increased, mostly affecting women and those over 50.

Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.

IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.

People with hidradenitis suppurativa are more likely to have bipolar disorder than those with psoriasis or without skin conditions.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Some chemicals and drugs can cause hair loss, which usually grows back after stopping the treatment.

Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.

Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Tranilast successfully treated a man's skin sarcoidosis when other treatments failed.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.